All Episodes
This Week in Addiction Medicine from ASAM — 117 episodes
Lead: Oral semaglutide for alcohol use disorder: A randomized clinical trial
Lead: Reflections on the preparation, implementation, and sustainability of a virtual SUD clinic: A public health response to the opioid epidemic
Lead: Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta-analysis Addiction
Lead: 2025 National Survey on Drug Use and Health (NSDUH)
Lead: Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: Multi-target trial emulation study
Lead: Trends in alcohol-related deaths in the United States over 55 years: 1968-2023
Lead: Comparison of buprenorphine treatment by virtual-only vs. traditional clinicians
Lead: Adjunctive psychosocial interventions and opioid abstinence among patients receiving buprenorphine: A randomized clinical trial
Lead: Alcohol intake and health study: No protective effect at low levels, with mortality increasing to 1 in 25 at 14 Drinks per week
Lead: Social media use trajectories and substance use experimentation: A prospective cohort study
Lead: Benzodiazepine tapering: Evidence limitations and research recommendations
Lead: Tobacco industry contributions to the development of ultraprocessed food in the United States, 1985–2007: A case study of Lunchables
Lead: GLP-1 receptor agonist treatment and health outcomes in methadone-treated patients with opioid use disorder and diabetes
Lead: Methamphetamine use among adult patients presenting with acute coronary syndrome: A single‐center retrospective cohort study
Lead: Best practices for hospital-based initiation of medications for opioid use disorder: A consensus statement
Lead: Access to medications for opioid use disorder among veterans with homeless experience in permanent supportive housing
Lead: Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements
Lead: Outpatient Direct Initiation of Injectable Buprenorphine in a Harm Reduction Agency and Primary Care Clinic: A Retrospective Case Series
Lead: A µ-opioid receptor superagonist analgesic with minimal adverse effects
Lead: Methadone Dose and Patient-Directed Discharge in Hospitalized Patients with Opioid Use Disorder
Lead: Do US Adults View Drug and Alcohol Addiction as a Health Condition?
Lead: Cannabis cessation and neurocognitive recovery: Patterns, predictors, and clinical implications—a systematic review
Lead: Cost-effectiveness of contingency management for methamphetamine use disorder: A model-based analysis
Lead: Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
Lead: Does the total consumption model apply to cannabis use?
Lead: Spirituality and Harmful or Hazardous Alcohol and Other Drug Use
Lead: Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
Lead: Use of gabapentin with or without a prescription in substance use treatment settings: A national analysis of urine drug testing data, 2016–2023
Lead: Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Lead: Medication Availability for Alcohol Use Disorder in Substance Use Disorder Treatment Facilities
Lead: Public Views About Opioid Overdose and People With Opioid Use Disorder
Lead: Did the illicit fentanyl trade experience a supply shock?
Lead: Barriers to Buprenorphine Initiation in Patients Using Fentanyl
Lead: Productivity Losses From Substance Use Disorder in the U.S. in 2023
Lead: Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations
Lead: Very Low Nicotine Content Cigarettes for Smoking Cessation: Examining a Facilitated Extinction Approach and Dosing Schedule
Lead: Fatal Opioid Overdoses by Historical and Contemporary Neighborhood-Level Structural Racism
Lead: State Laws Banning Prior Authorization For Medications For Opioid Use Disorder Increased Substantially, 2015–23
Lead: Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine
Lead: States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018–24
Lead: Ultra-processed food addiction in a nationally representative sample of older adults in the USA
Lead: Alcohol Consumption Per Capita and Suicide: A Meta-Analysis
Lead: Measures of General Intelligence and Risk for Alcohol Use Disorder
Lead: Medications for Opioid Use Disorder Playbook
Lead: Cannabis Use During Pregnancy and Lactation
Lead: Contingency Management for Stimulant Use Disorder and Association With Mortality: A Cohort Study
Lead: Machine learning– and multilayer molecular network–assisted screening hunts fentanyl compound
Lead: Evaluation of a Novel Patient-Centered Methadone Restart Protocol
Lead: Recommendations for Addressing In-Hospital Substance Use From a National Delphi Consensus Process
Lead: Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting
Lead: Association between housing status and mental health and substance use severity among individuals with opioid use disorder and co-occurring depression and/or PTSD
Lead: Oral methadone versus sublingual buprenorphine for the treatment of acute opioid withdrawal: A triple-blind, double-dummy, randomized control trial
Lead: Implementation Gaps in US Syringe Service Programs, 2022
Lead: Co-involvement of stimulants with opioids in North America: A 'silent epidemic’
Lead: Did alcohol facilitate the evolution of complex societies?
Lead: Disparities in Treatment and Referral After an Opioid Overdose Among Emergency Department Patients
Lead: Prescriber-Level Changes in Buprenorphine Dispensing in the USA Before and After Federal Policy Changes Aimed at Increasing Prescribing
Lead: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits
Lead: Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study
Lead: Bitter sensing protects Drosophila from developing experience-dependent cocaine consumption preference
Lead: Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons
Lead: Medicaid Unwinding and Changes in Buprenorphine Dispensing
Lead: Loneliness Among US Veterans With Problematic Substance Use: Results From the National Health and Resilience in Veterans Study
Lead: The IARC Perspective on the Effects of Policies on Reducing Alcohol Consumption
Lead: Building Multidisciplinary Consensus on Inpatient Xylazine Management through Clinical Protocols
Lead: Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial
Lead: Comprehensive drug policies increase trust in local government: an analysis of authorities’ and residents’ perspectives in rural US Appalachian and Midwestern counties
Lead: Hospital Addiction Consultation Service and Opioid Use Disorder Treatment
Lead: Averted lung cancer deaths due to reductions in cigarette smoking in the United States, 1970–2022
Lead: Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years
Lead: Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans
Lead: Association Between Telehealth Initiation Of Stimulant Therapy And New Substance Use Disorder Diagnoses
Lead: The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021
Lead: Illicit Substance Use and Treatment Access Among Adults Experiencing Homelessness
Lead: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
Lead: Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality
Lead: Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders
Lead: Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl
Lead: Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning
Lead: Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice
ASAM Weekly Special Episode: Dr. David Fiellin & Dr. Eric Strain sit down to discuss the concept of Treatment Refractory Addiction
Lead: Review of Evidence on Alcohol and Health
Lead: The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies
Lead: Prevalence of pharmacotherapy for attention-deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students
Lead: Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and Xylazine
Lead: Suicide in people prescribed opioid-agonist therapy in Scotland, United Kingdom, 2011–2020: A national retrospective cohort study
Lead: Links between adolescent binge drinking and midlife alcohol use behaviors by age, sex, and race/ethnicity
Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder
Lead: Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization
Lead: Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review
Lead: Cannabis Policy Impacts Public Health and Health Equity
ASAM Weekly Special Episode: Dr. Shannon Miller talks PAM-7 and his path to addiction medicine [From the ASAM 55th Annual Conference]
Lead: Risk of Incident Psychosis and Mania With Prescription Amphetamines
Lead: Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders
Lead: State-level racial and ethnic disparities in buprenorphine treatment duration in the United States
Lead: Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial
Lead: The Lancet Psychiatry Commission on youth mental health
Lead: Alcohol Consumption Patterns and Mortality Among Older Adults With Health-Related or Socioeconomic Risk Factors
Lead: Physician Reluctance to Intervene in Addiction: A Systematic Review
ASAM Weekly Special Episode: Rapid Initiation of Injection Naltrexone for OUD | Dr. Matisyahu Shulman & Dr. Adam Bisaga
Lead: Social Vulnerability and Prevalence and Treatment for Mental Health and Substance Use Disorders
Lead: Psilocybin desynchronizes the human brain
Lead: Secondhand Nicotine Absorption From E-Cigarette Vapor vs Tobacco Smoke in Children
Lead: Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study
Lead: Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
Lead: Global status report on alcohol and health and treatment of substance use disorders
Lead: Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths
Lead: Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl
Lead: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Lead: Innovation and adaptation: The rise of a fentanyl smoking culture in San Francisco
Lead: Rapid Initiation of Injection Naltrexone for Opioid Use Disorder
Lead: Burden of Mental Disorders and Suicide Attributable to Childhood Maltreatment
Lead: Associations of cannabis use, use frequency, and cannabis use disorder with violent behavior among young adults in the United States
Lead: Biomarkers of metal exposure in adolescent e-cigarette users
Lead: Association of regular opioid use with incident dementia and neuroimaging markers of brain health in chronic pain patients
Lead: Preventing deaths after prison release
Lead: Telling the story of the opioid crisis